Sporadic CDKN2 (MTSlIpl6inkI) gene alterations in human ovarian tumours
1996

CDKN2 Gene Alterations in Ovarian Cancer

Sample size: 37 publication Evidence: low

Author Information

Author(s): M Schuyerl, IL van Staveren, JGM Klijnl, MEL v.d. Burg, G Stoterl, SC Henzen-Logmans, JA Foekens, EMJJ Berns

Primary Institution: Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Hypothesis

Are CDKN2 gene alterations involved in ovarian carcinogenesis?

Conclusion

CDKN2 gene alterations are infrequent in both primary and metastatic ovarian adenocarcinomas.

Supporting Evidence

  • Only 28% of primary tumors showed altered migration patterns for the CDKN2 gene.
  • 46% of ovarian tumor specimens had mutations in the TP53 gene.
  • Two cell lines showed alterations in the CDKN2 gene, with one being homozygously deleted.

Takeaway

The study looked at a gene called CDKN2 in ovarian cancer and found that changes in this gene are not common, which means it likely doesn't play a big role in causing ovarian cancer.

Methodology

The study analyzed CDKN2 gene alterations in 32 primary and 5 metastatic ovarian adenocarcinomas and 5 ovarian cancer cell lines using PCR-SSCP and sequencing techniques.

Limitations

The low prevalence of CDKN2 gene alterations may be due to technical difficulties and the presence of non-neoplastic cell content in tumor samples.

Participant Demographics

The mean age of patients with ovarian tumors was 56 years, with a range from 26 to 85 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication